{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/634549cdd950350012c90fc5/6ae0aad033b363c95ddb1827?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"What are the implications of the PHOENYCS GO trial for the SLE treatment landscape? ","description":"<p>The Lupus Hub was pleased to speak with Zahi Touma, University of Toronto and University Health Network, Ontario, CA. We asked, What are the implications of the PHOENYCS GO trial for the SLE treatment landscape? </p><p><br></p><p>During this interview, Touma discusses the unmet need for therapies that provide broad and durable disease control in systemic lupus erythematosus (SLE) while minimizing glucocorticoid exposure, the mechanism of action of dapirolizumab pegol as a CD40 ligand (CD40L) inhibitor, and the clinical evidence supporting its development. He highlights findings from the phase III PHOENYCS GO trial (NCT04294667), including achievement of the primary endpoint and improvements across multiple measures of disease activity, disease control, fatigue, and glucocorticoid tapering, as well as an acceptable and manageable safety profile. Touma also discusses the ongoing PHOENYCS FLY trial (NCT06617325), which may further establish the role of dapirolizumab pegol in patients with moderate-to-severe disease. </p><p><br></p><p>Intended for healthcare professionals. This educational resource is independently supported by Biogen MA, Inc. and UCB. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence. </p>","author_name":"Scientific Education Support"}